Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel C Cho

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Cancer|June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapyDaniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
Cancer Research Communications|December 20, 2023
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I StudyPamela Munster, Nicholas Iannotti, Daniel C Cho, et al.
Cancer Research Communications|March 13, 2024
Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I StudyPamela Munster, Nicholas Iannotti, Daniel C Cho, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinomaDaniel C Cho, Igor Puzanov, Meredith M Regan, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2016
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid TumorsVandana G Abramson, Jeffrey G Supko, Tarah Ballinger, et al.
Urologic Oncology|May 11, 2010
Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinomaAymen A Elfiky, Daniel C Cho, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell CarcinomaJean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
The Lancet. Oncology|February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Cancer|June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapyDaniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
Cancer Research Communications|December 20, 2023
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I StudyPamela Munster, Nicholas Iannotti, Daniel C Cho, et al.
Cancer Research Communications|March 13, 2024
Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I StudyPamela Munster, Nicholas Iannotti, Daniel C Cho, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinomaDaniel C Cho, Igor Puzanov, Meredith M Regan, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2016
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid TumorsVandana G Abramson, Jeffrey G Supko, Tarah Ballinger, et al.
Urologic Oncology|May 11, 2010
Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinomaAymen A Elfiky, Daniel C Cho, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell CarcinomaJean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
The Lancet. Oncology|February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Pageof 5